Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21703579 | 0.83 | SLC6A4 (0.36) | CHRM3SIGMAR1 | |
| SCHEMBL3106302 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL3103675 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL10386726 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL2801591 | 0.72 | SMN1; SMN2 (0.54) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL7333857 | 0.70 | SMN1; SMN2 (0.43) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL208440 | 0.69 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL6921848 | 0.69 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL20386598 | 0.69 | CXCR4 (0.44) | SMN1; SMN2CHRM5CHRM3SIGMAR1 | |
| SCHEMBL15284195 | 0.69 | CHRM2 (0.50) | SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | SMN1; SMN2 3073/4885CHRM5 1027/4885CHRM3 382/4885 |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | PRF1, NOX1, ARG1 | SMN1; SMN2 3073/4885CHRM5 1027/4885CHRM3 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.